ALIM up +3.63% percent Today $ALIM High is at 5.54
Post# of 51
Posted On: 11/17/2014 3:11:17 PM
ALIM up +3.63% percent Today $ALIM High is at 5.54 and the Low 5.33 with current volume of 119,922.
Recent News posted below.
Alimera Sciences ALIM other info.
http://investorshangout.com/Alimera-Sciences-ALIM-53276/
ALIM Alimera Sciences Recent Headline News
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Ireland For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Nov 17, 10:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Irish Health Products Regulatory Authority (HPRA) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.31 (+0.07)
Alimera Sciences wins marketing authorisation in Belgium for ILUVIEN for chronic diabetic macular edema
M2 - Thu Nov 13, 7:08AM CST
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) reported on Thursday the receipt of the Belgian Federal Agency for Medicines and Health Products' (FAMHP) marketing approval for ILUVIEN for treating vision impairment with chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
ALIM: 5.31 (+0.07)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Belgium For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Wed Nov 12, 6:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.31 (+0.07)
Alimera Sciences' (ALIM) CEO Daniel Myers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 10:46PM CST
ALIM: 5.31 (+0.07)
Alimera Sciences beats by $0.48, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:19PM CST
ALIM: 5.31 (+0.07)
Alimera Sciences (ALIM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
ALIM: 5.31 (+0.07)
Alimera Sciences Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 3:13PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the third quarter ended September 30, 2014.
ALIM: 5.31 (+0.07)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.63 (+0.03), ACET: 21.02 (-0.08), ANET: 76.69 (-1.00), FNGN: 32.57 (-0.34), CPST: 0.87 (-0.06), AUQ: 3.91 (+0.13), AMRN: 1.07 (+0.12), ED: 62.64 (+0.61), ENV: 53.03 (-1.47), FXCM: 16.36 (-0.30), BCEI: 37.49 (-1.62), GXP: 26.48 (+0.10), EAC: 11.40 (-0.56), DXCM: 51.90 (-0.83), CSC: 62.49 (+0.73), AEL: 27.04 (-0.16), HNSN: 0.83 (-0.01), CFN: 57.62 (+0.05), ANAC: 31.13 (+0.13), DAR: 18.95 (+0.14), GST: 4.11 (-0.01), ARC: 9.38 (-0.21), FIVN: 4.93 (-0.04), ELON: 1.91 (unch), FSLR: 47.93 (-0.56), EZPW: 10.80 (-0.17), ALIM: 5.31 (+0.07), FWM: 2.30 (unch), BRS: 70.60 (-0.20), ECOM: 18.31 (-0.54), FTEK: 4.14 (+0.29), CVT: 27.22 (-0.93), AL: 36.80 (-0.17), BBRG: 13.03 (-0.12), BPZ: 0.95 (-0.05), ECPG: 44.51 (-0.11), HTGC: 15.58 (+0.02), AIRM: 44.47 (+0.25), BNFT: 24.78 (-1.87), ENOC: 14.89 (-0.32), HPTX: 20.89 (-0.30), AGO: 24.94 (unch), FICO: 71.96 (+0.52), FF: 12.25 (-0.17), FI: 20.86 (+0.23), EVC: 5.50 (+0.04), EBS: 24.18 (-0.04), ABCO: 45.42 (-0.96), DIOD: 25.89 (-0.45), DIS: 90.51 (-0.29), EGOV: 17.59 (-0.18), APEI: 36.09 (-0.53), DVA: 75.47 (-0.19), CLVS: 53.82 (-1.07), HCI: 42.55 (-0.49), BRKR: 18.29 (+0.18), HGR: 19.66 (-1.54)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 8.57 (+0.54), ALIM: 5.31 (+0.07), ACHN: 13.40 (-0.57), FNHC: 24.16 (-0.57), ARCP: 8.77 (+0.04), CKEC: 28.37 (-0.10), JAXB: 11.11 (-0.64), PCLN: 1,167.81 (-5.15), TESO: 15.76 (-0.21)
Alimera Sciences to Release Third Quarter 2014 Results
PR Newswire - Thu Oct 23, 3:15PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will release its third quarter of fiscal year 2014 financial results after the market close on Thursday, November 6, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET.
ALIM: 5.31 (+0.07)
Alimera Sciences to Present at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting
PR Newswire - Thu Oct 09, 7:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will present at the Ophthalmology Innovation Summit (OIS) at the American Academy of Ophthalmology (AAO) annual meeting in Chicago, IL.
ALIM: 5.31 (+0.07)
Nasdaq stocks posting largest volume increases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
PDFS: 13.30 (-0.52), IKAN: 0.32 (-0.03), SANW: 3.34 (-0.32), TIBX: 23.68 (-0.04), ALIM: 5.31 (+0.07), MOVE: 20.95 (-0.03), SPEX: 1.43 (+0.08), MBTF: 4.87 (+0.01), ELGX: 11.51 (+0.03), SMPL: 16.46 (-0.12)
Why Alimera Sciences (ALIM) Stock Is Up Today
at The Street - Tue Sep 30, 3:14PM CDT
Shares of Alimera Sciences (ALIM) are up after the company announced it had received a $25 million advance from Hercules Technology Growth Capital (HTGC).
HTGC: 15.58 (+0.02), ALIM: 5.31 (+0.07)
Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital
PR Newswire - Tue Sep 30, 12:50PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules). The payment is the second and final advance under the Loan and Security Agreement that Alimera's subsidiary in the United Kingdom, Alimera Sciences Limited, entered into with Hercules in April of this year. Receipt of the $25 million was conditional on the approval, on or before October 31, 2014, of ILUVIEN® by the U.S. Food and Drug Administration (FDA). On September 26, 2014, the FDA approved ILUVIEN® for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
HTGC: 15.58 (+0.02), ALIM: 5.31 (+0.07)
Alimera/pSivida's Iluvien Receives FDA Approval for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:55PM CDT
Alimera Sciences, Inc.'s (ALIM) announced that the FDA has approved Iluvien for the long-term treatment of diabetic macular edema (DME).
CBM: 23.00 (-0.17), GILD: 101.02 (-1.04), ALIM: 5.31 (+0.07), PSDV: 3.58 (-0.09)
Why Alimera Sciences (ALIM) Stock Is Gaining Today
at The Street - Mon Sep 29, 2:22PM CDT
Alimera Sciences (ALIM) shares continue to rise after having its Iluvien treatment approved by the FDA.
ALIM: 5.31 (+0.07)
Alimera Sciences Provides Details On FDA Approval Of ILUVIEN® As The First Long-Term Treatment For Diabetic Macular Edema
PR Newswire - Mon Sep 29, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"
, a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will hold a conference call to provide additional information regarding the recent approval by the U.S. Food and Drug Administration (FDA) of ILUVIEN® for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). ILUVIEN was approved without any restriction requiring patients to have undergone, or be scheduled for, cataract surgery.
ALIM: 5.31 (+0.07)
Alimera Sciences wins US FDA approval for ILUVIEN for diabetic macular edema
M2 - Mon Sep 29, 6:07AM CDT
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) revealed on Friday that it has received approval from the US Food and Drug Administration (FDA) for ILUVIEN for the treatment of diabetic macular edema (DME), with plans to market the drug in the Q1 2015.
ALIM: 5.31 (+0.07)
Recent News posted below.
Alimera Sciences ALIM other info.
http://investorshangout.com/Alimera-Sciences-ALIM-53276/
ALIM Alimera Sciences Recent Headline News
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Ireland For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Nov 17, 10:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Irish Health Products Regulatory Authority (HPRA) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.31 (+0.07)
Alimera Sciences wins marketing authorisation in Belgium for ILUVIEN for chronic diabetic macular edema
M2 - Thu Nov 13, 7:08AM CST
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) reported on Thursday the receipt of the Belgian Federal Agency for Medicines and Health Products' (FAMHP) marketing approval for ILUVIEN for treating vision impairment with chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
ALIM: 5.31 (+0.07)
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Belgium For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Wed Nov 12, 6:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.31 (+0.07)
Alimera Sciences' (ALIM) CEO Daniel Myers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 10:46PM CST
ALIM: 5.31 (+0.07)
Alimera Sciences beats by $0.48, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:19PM CST
ALIM: 5.31 (+0.07)
Alimera Sciences (ALIM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
ALIM: 5.31 (+0.07)
Alimera Sciences Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 3:13PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the third quarter ended September 30, 2014.
ALIM: 5.31 (+0.07)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.63 (+0.03), ACET: 21.02 (-0.08), ANET: 76.69 (-1.00), FNGN: 32.57 (-0.34), CPST: 0.87 (-0.06), AUQ: 3.91 (+0.13), AMRN: 1.07 (+0.12), ED: 62.64 (+0.61), ENV: 53.03 (-1.47), FXCM: 16.36 (-0.30), BCEI: 37.49 (-1.62), GXP: 26.48 (+0.10), EAC: 11.40 (-0.56), DXCM: 51.90 (-0.83), CSC: 62.49 (+0.73), AEL: 27.04 (-0.16), HNSN: 0.83 (-0.01), CFN: 57.62 (+0.05), ANAC: 31.13 (+0.13), DAR: 18.95 (+0.14), GST: 4.11 (-0.01), ARC: 9.38 (-0.21), FIVN: 4.93 (-0.04), ELON: 1.91 (unch), FSLR: 47.93 (-0.56), EZPW: 10.80 (-0.17), ALIM: 5.31 (+0.07), FWM: 2.30 (unch), BRS: 70.60 (-0.20), ECOM: 18.31 (-0.54), FTEK: 4.14 (+0.29), CVT: 27.22 (-0.93), AL: 36.80 (-0.17), BBRG: 13.03 (-0.12), BPZ: 0.95 (-0.05), ECPG: 44.51 (-0.11), HTGC: 15.58 (+0.02), AIRM: 44.47 (+0.25), BNFT: 24.78 (-1.87), ENOC: 14.89 (-0.32), HPTX: 20.89 (-0.30), AGO: 24.94 (unch), FICO: 71.96 (+0.52), FF: 12.25 (-0.17), FI: 20.86 (+0.23), EVC: 5.50 (+0.04), EBS: 24.18 (-0.04), ABCO: 45.42 (-0.96), DIOD: 25.89 (-0.45), DIS: 90.51 (-0.29), EGOV: 17.59 (-0.18), APEI: 36.09 (-0.53), DVA: 75.47 (-0.19), CLVS: 53.82 (-1.07), HCI: 42.55 (-0.49), BRKR: 18.29 (+0.18), HGR: 19.66 (-1.54)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 8.57 (+0.54), ALIM: 5.31 (+0.07), ACHN: 13.40 (-0.57), FNHC: 24.16 (-0.57), ARCP: 8.77 (+0.04), CKEC: 28.37 (-0.10), JAXB: 11.11 (-0.64), PCLN: 1,167.81 (-5.15), TESO: 15.76 (-0.21)
Alimera Sciences to Release Third Quarter 2014 Results
PR Newswire - Thu Oct 23, 3:15PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will release its third quarter of fiscal year 2014 financial results after the market close on Thursday, November 6, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET.
ALIM: 5.31 (+0.07)
Alimera Sciences to Present at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting
PR Newswire - Thu Oct 09, 7:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will present at the Ophthalmology Innovation Summit (OIS) at the American Academy of Ophthalmology (AAO) annual meeting in Chicago, IL.
ALIM: 5.31 (+0.07)
Nasdaq stocks posting largest volume increases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
PDFS: 13.30 (-0.52), IKAN: 0.32 (-0.03), SANW: 3.34 (-0.32), TIBX: 23.68 (-0.04), ALIM: 5.31 (+0.07), MOVE: 20.95 (-0.03), SPEX: 1.43 (+0.08), MBTF: 4.87 (+0.01), ELGX: 11.51 (+0.03), SMPL: 16.46 (-0.12)
Why Alimera Sciences (ALIM) Stock Is Up Today
at The Street - Tue Sep 30, 3:14PM CDT
Shares of Alimera Sciences (ALIM) are up after the company announced it had received a $25 million advance from Hercules Technology Growth Capital (HTGC).
HTGC: 15.58 (+0.02), ALIM: 5.31 (+0.07)
Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital
PR Newswire - Tue Sep 30, 12:50PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules). The payment is the second and final advance under the Loan and Security Agreement that Alimera's subsidiary in the United Kingdom, Alimera Sciences Limited, entered into with Hercules in April of this year. Receipt of the $25 million was conditional on the approval, on or before October 31, 2014, of ILUVIEN® by the U.S. Food and Drug Administration (FDA). On September 26, 2014, the FDA approved ILUVIEN® for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
HTGC: 15.58 (+0.02), ALIM: 5.31 (+0.07)
Alimera/pSivida's Iluvien Receives FDA Approval for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:55PM CDT
Alimera Sciences, Inc.'s (ALIM) announced that the FDA has approved Iluvien for the long-term treatment of diabetic macular edema (DME).
CBM: 23.00 (-0.17), GILD: 101.02 (-1.04), ALIM: 5.31 (+0.07), PSDV: 3.58 (-0.09)
Why Alimera Sciences (ALIM) Stock Is Gaining Today
at The Street - Mon Sep 29, 2:22PM CDT
Alimera Sciences (ALIM) shares continue to rise after having its Iluvien treatment approved by the FDA.
ALIM: 5.31 (+0.07)
Alimera Sciences Provides Details On FDA Approval Of ILUVIEN® As The First Long-Term Treatment For Diabetic Macular Edema
PR Newswire - Mon Sep 29, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"
, a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will hold a conference call to provide additional information regarding the recent approval by the U.S. Food and Drug Administration (FDA) of ILUVIEN® for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). ILUVIEN was approved without any restriction requiring patients to have undergone, or be scheduled for, cataract surgery. ALIM: 5.31 (+0.07)
Alimera Sciences wins US FDA approval for ILUVIEN for diabetic macular edema
M2 - Mon Sep 29, 6:07AM CDT
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) revealed on Friday that it has received approval from the US Food and Drug Administration (FDA) for ILUVIEN for the treatment of diabetic macular edema (DME), with plans to market the drug in the Q1 2015.
ALIM: 5.31 (+0.07)
(0)
(0)Alimera Sciences Inc. (ALIM) Stock Research Links
Scroll down for more posts ▼